المؤلفون: Clamp, AR, James, EC, McNeish, IA, Dean, A, Kim, J-W, O'Donnell, DM, Gallardo-Rincon, D, Blagden, S, Brenton, J, Perren, TJ, Sundar, S, Lord, R, Dark, G, Hall, M, Banerjee, S, Glasspool, RM, Hanna, CL, Williams, S, Scatchard, KM, Nam, H, Essapen, S, Parkinson, C, McAvan, L, Swart, AM, Popoola, B, Schiavone, F, Badrock, J, Fananapazir, F, Cook, AD, Parmar, M, Kaplan, R, Ledermann, JA

المساهمون: Banerjee, Susana

مصطلحات موضوعية: Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Ovarian Epithelial, Fallopian Tubes, Female, Humans, Middle Aged, Ovarian Neoplasms, Paclitaxel

جغرافية الموضوع: England

وصف الملف: Print-Electronic; 930; application/pdf

العلاقة: S1470-2045(22)00283-2; The Lancet Oncology, 2022, 23 (7), pp. 919 - 930; https://repository.icr.ac.uk/handle/internal/5475Test

الإتاحة: https://doi.org/10.1016/S1470-2045Test(22)00283-2
https://repository.icr.ac.uk/handle/internal/5475Test

المؤلفون: Colomban, O, Tod, M, Peron, J, Perren, TJ, Leary, A, Cook, AD, Sajous, C, Freyer, G, You, B

المصدر: JNCI Cancer Spectrum , 4 (3) , Article pkaa026. (2021)

مصطلحات موضوعية: chemotherapy regimen, ca-125 antigen, phase 3 clinical trials, kinetics, neoplasms, ovarian cancer, bevacizumab, elimination rate constant, progression-free survival, datasets

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10123745/1/pkaa026.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10123745Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10123745/1/pkaa026.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10123745Test/

المؤلفون: Ledermann, JA, Embleton-Thirsk, AC, Perren, TJ, Jayson, GC, Rustin, GJS, Kaye, SB, Hirte, H, Oza, A, Vaughan, M, Friedlander, M, González-Martín, A, Deane, E, Popoola, B, Farrelly, L, Swart, AM, Kaplan, RS, Parmar, MKB, ICON6 collaborators, .

المصدر: ESMO Open , 6 (2) , Article 100043. (2021)

مصطلحات موضوعية: clinical trial, oncology, ovarian, overall survival, phase III

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/10122196/1/Ledermann%20et%20al.%20-%202021%20-%20Cediranib%20in%20addition%20to%20chemotherapy%20for%20women%20wi.pdfTest; https://discovery.ucl.ac.uk/id/eprint/10122196Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/10122196/1/Ledermann%20et%20al.%20-%202021%20-%20Cediranib%20in%20addition%20to%20chemotherapy%20for%20women%20wi.pdfTest
https://discovery.ucl.ac.uk/id/eprint/10122196Test/

المؤلفون: Hall, M, Bertelli, G, Li, L, Green, C, Chan, S, Yeoh, CC, Hasan, J, Jones, R, Ograbek, A, Perren, TJ

وصف الملف: text

العلاقة: https://eprints.whiterose.ac.uk/167611/1/213.full.pdfTest; Hall, M, Bertelli, G, Li, L et al. (7 more authors) (2020) Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. International Journal of Gynecological Cancer, 30 (2). pp. 213-220. ISSN 1048-891X

الإتاحة: https://eprints.whiterose.ac.uk/167611Test/
https://eprints.whiterose.ac.uk/167611/1/213.full.pdfTest

المؤلفون: Colomban, O, Tod, M, Peron, J, Perren, TJ, Leary, A, Cook, AD, Sajous, C, Freyer, G, You, B

وصف الملف: text

العلاقة: https://eprints.whiterose.ac.uk/167360/1/Bevacizumab%20for%20Newly%20Diagnosed%20Ovarian%20Cancers%20Best%20Candidates%20Among%20High-Risk%20Disease%20Patients%20%28ICON-7%29.pdfTest; Colomban, O, Tod, M, Peron, J et al. (6 more authors) (2020) Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7). JNCI Cancer Spectrum, 4 (3). pkaa026. pkaa026-. ISSN 1475-4029

الإتاحة: https://eprints.whiterose.ac.uk/167360Test/
https://eprints.whiterose.ac.uk/167360/1/Bevacizumab%20for%20Newly%20Diagnosed%20Ovarian%20Cancers%20Best%20Candidates%20Among%20High-Risk%20Disease%20Patients%20%28ICON-7%29.pdfTest

المؤلفون: Laes, J-F, Aftimos, P, Barthelemy, P, Bellmunt, J, Berchem, G, Camps, C, de las Peñas, R, Finzel, A, García-Foncillas, J, Hervonen, P, Wahid, I, Joensuu, T, Kathan, L, Kong, A, Mackay, J, Mikropoulos, C, Mokbel, K, Mouysset, J-L, Odarchenko, S, Perren, TJ, Pienaar, R, Regonesi, C, Alkhayyat, SS, El Kinge, AR, Abulkhair, O, Galal, KM, Ghanem, H, El Karak, F, Garcia, A, Ghitti, G, Sadik, H

وصف الملف: text

العلاقة: https://eprints.whiterose.ac.uk/136561/1/The%20clinical%20impact%20of%20using%20complex%20molecular%20profiling%20strategies%20in%20routine%20oncology%20practice.pdfTest; Laes, J-F, Aftimos, P, Barthelemy, P et al. (28 more authors) (2018) The clinical impact of using complex molecular profiling strategies in routine oncology practice. Oncotarget, 9 (29). pp. 20282-20293. ISSN 1949-2553

الإتاحة: https://eprints.whiterose.ac.uk/136561Test/
https://eprints.whiterose.ac.uk/136561/1/The%20clinical%20impact%20of%20using%20complex%20molecular%20profiling%20strategies%20in%20routine%20oncology%20practice.pdfTest

المؤلفون: McNeish, I, Clamp, A, James, EC, Dean, A, Kim, J-W, O’Donnell, DM, Gallardo-Rincon, D, Blagden, S, Brenton, J, Perren, TJ, Sundar, S, Lord, R, Dark, G, Hall, M, Banerjee, S, Glasspool, RM, Hanna, L, Williams, S, Scratchard, KM, Nam, H, Essapen, S, Parkinson, C, McAvan, L, Swart, AM, Popoola, B, Schiavone, F, Badrock, J, Fananapazir, F, Cook, AD, Parmar, M, Kaplan, R, Ledermann, JA

المساهمون: Ovarian Cancer Action, National Institute for Health Research

مصطلحات موضوعية: 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______1032::17c3c5e9aea946d9d3b2babae950d996Test
http://hdl.handle.net/10044/1/97299Test

المؤلفون: Oza, AM, Cook, AD, Pfisterer, J, Embleton, A, Ledermann, JA, Pujade-Lauraine, E, Kristensen, G, Carey, MS, Beale, P, Cervantes, A, Park-Simon, TW, Rustin, G, Joly, F, Mirza, MR, Plante, M, Quinn, M, Poveda, A, Jayson, GC, Stark, D, Swart, AM, Farrelly, L, Kaplan, R, Parmar, MK, Perren, TJ, ICON7, trial investigators

المصدر: Lancet Oncology , 16 (8) pp. 928-936. (2015)

وصف الملف: text

العلاقة: https://discovery.ucl.ac.uk/id/eprint/1469584/6/Oza_Standard%20chemotherapy%20with%20or%20without%20bevacizumab%20for%20women%20with.pdfTest; https://discovery.ucl.ac.uk/id/eprint/1469584Test/

الإتاحة: https://discovery.ucl.ac.uk/id/eprint/1469584/6/Oza_Standard%20chemotherapy%20with%20or%20without%20bevacizumab%20for%20women%20with.pdfTest
https://discovery.ucl.ac.uk/id/eprint/1469584Test/

المؤلفون: Stevens, W, Farrow, IM, Georgiou, L, Hanby, AM, Perren, TJ, Windel, LM, Wilson, DJ, Sharma, N, Dodwell, D, Hughes, TA, Dall, BJG, Buckley, DL

العلاقة: Stevens, W, Farrow, IM, Georgiou, L et al. (9 more authors) (2021) Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response. The British Journal of Radiology. 20201396-. ISSN 0007-1285

الإتاحة: https://eprints.whiterose.ac.uk/175144Test/

المؤلفون: Hall, M, Bertelli, G, Li, L, Green, C, Chan, S, Yeoh, CC, Hasan, Jurjees, Ograbek, A, Perren, TJ

المساهمون: Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK

العلاقة: https://dx.doi.org/10.1093/annonc/mdy285.191Test; Hall M, Bertelli G, Li L, Green C, Chan S, Yeoh CC, et al. 984P Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC). Annals of Oncology. 2018;29(suppl_8).; No PMID; http://hdl.handle.net/10541/621719Test; Annals of Oncology

الإتاحة: https://doi.org/10.1093/annonc/mdy285.191Test
http://hdl.handle.net/10541/621719Test